CHAPTER 234

Clotting Disorders

Jessie G. Nelson

REFERENCES

1. Weingarz L, Schwonberg J, Schindewolf M, et al: Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAIST-HRO registry. *Br J Haematol* 163: 655, 2013. [PMID: 24219332]
2. Simone B, De Stefano, Leoncini E, et al: Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. *Eur J Epidemiol* 28: 621, 2013. [PMID: 23900608]
3. MacCallum P, Bowles L, Keeling D: Diagnosis and management of heritable thrombophilias. *BMJ* 349: g4387, 2014. [PMID: 25035247]
4. Pruthi, RK: Optimal utilization of thrombophilia testing. *Int J Lab Hematol* 39: 104, 2017. [PMID: 28447412]
5. Wells PS, Anderson DR, Rodger M, et al: Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the model's utility with the SimpliRED D-dimer. *Thromb Haemost* 83: 416, 2000. [PMID: 10744147]
6. Kline JA, Mitchel AM, Kabrhel C, et al: Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. *J Thromb Haemost* 2: 1247, 2004. [PMID: 15304025]
7. Streiff MB, Agnelli G, Connors JM, et al: Guidance for the treatment of deep vein thrombosis and pulmonary embolism. *J Thromb Thrombolysis* 41: 32, 2016. [PMID: 26780738]
8. van Mens TE, Levi M, Middeldorp S: Evolution of factor V Leiden. *Thromb Haemost* 110: 23, 2013. [PMID: 23615810]
9. Hirmerova J, Seidlerova J, Subrt I: The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox. *QJM* 107: 715, 2014. [PMID: 24633260]
10. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW: Risk of recurrent venous thromboembolism in patients with common thrombophilia. *Arch Intern Med* 66: 729, 2006. [PMID: 16606808]
11. Fischer R, Sachs UJ, Heidinger KS, Eisenburger D, Kemkes-Matthes B: Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events. *Blood Coagul Fibrinolysis* 24: 444, 2013. [PMID: 23429250]
12. Miyata T, Sato Y, Ishikawa J, et al: Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. *Thromb Res* 124: 14, 2009. [PMID: 18954896]
13. Undas A, Goralczyk T: Direct oral anticoagulants in patients with thrombophilia: challenges in diagnostic evaluation and treatment. *Adv Clin Exp Med* 25: 1321, 2016. [PMID: 28028988]
14. Fu Y, Wang X, Kong W: Hyperhomocysteinemia and vascular injury: the advance of mechanisms and drug targets. *Br J Pharmacol* 175: 1173, 2017. [PMID: 28836260]
15. Vasan SK, Rostgaard K, Majeed A, et al: ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. *Circulation* 133: 1449, 2016. [PMID: 26939588]
16. Barco S, Nijkeuter M, Middeldorp S: Pregnancy and venous thromboembolism. *Semin Thromb Hemost* 39: 549, 2013. [PMID: 23633191]
17. Sousou T, Khorana AA: New insights into cancer related thrombosis. *Arterioscler Thromb Vasc Biol* 29: 316, 2009. [PMID: 19228604]
18. Lyman GH, Bohlke K, Khorana AA, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. *J Clin Oncol* 33: 654, 2015. [PMID: 25605844]
19. Schmaier AA, Ambesh P, Campia U: Venous thromboembolism and cancer. *Curr Cardiol Rep* 20: 89, 2018. [PMID: 30128839]
20. Voigtlaender M, Langer F. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far? *Hamostaseologie* 37: 241, 2017. [PMID: 28508916]
21. Arepally GM: Heparin-induced thrombocytopenia. *Blood* 129: 2864, 2017. [PMID: 28416511]
22. Fathi M: Heparin-induced thrombocytopenia (HIT): identification and treatment pathways. *Glob Cardiol Sci Pract* 2018: 15, 2018. [PMID: 30083545]
23. Thornsberry LA, LoSicco KI, English JC 3rd: The skin and hypercoagulable states. *J Am Acad Dermatol* 69: 450, 2013. [PMID: 23582572]
24. Cervera R: Antiphospholipid syndrome. *Thromb Res* 151: S43, 2017. [PMID: 28262233]
25. Andreoli L, Chighizola CB, Banzato A, et al: Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. *Arthritis Care Res (Hoboken)* 65: 1869, 2013. [PMID: 23861221]
26. Arachchillage DR, Laffan M: Pathogenesis and management of antiphospholipid syndrome. *Br J Haematol* 178: 181, 2017. [PMID: 28339096]
27. Streiff MB: Predicting the risk of recurrent venous thromboembolism (VTE). *J Thromb Thrombolysis* 39: 353, 2015. [PMID: 25721218]
28. Domingueti CP, Dusse LM, Carvalho MD, De Sousa LP, Gomes KB, Fernandes AP: Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. *J Diabetes Compl* 30: 738, 2016. [PMID: 26781070]
29. Baker JV: Chronic HIV disease and activation of the coagulation system. *Thromb Res* 132: 495, 2013. [PMID: 24034985]